

Michael D Wyatt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8050424/michael-d-wyatt-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

5,827
citations

29
h-index

76
g-index

78
ext. papers

6,293
ext. citations

6.6
avg, IF

5.45
L-index

#	Paper	IF	Citations
74	Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. <i>European Journal of Medicinal Chemistry</i> , 2022 , 227, 113926	6.8	0
73	Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 9916-9925	8.3	1
72	Panaxynol, a bioactive component of American ginseng, targets macrophages and suppresses colitis in mice. <i>Oncotarget</i> , 2020 , 11, 2026-2036	3.3	5
71	Microbes as Drugs: The Potential of Pharmabiotics. <i>Pharmacotherapy</i> , 2020 , 40, 102-106	5.8	6
70	Inhibition of the Dead Box RNA Helicase 3 Prevents HIV-1 Tat and Cocaine-Induced Neurotoxicity by Targeting Microglia Activation. <i>Journal of NeuroImmune Pharmacology</i> , 2020 , 15, 209-223	6.9	7
69	Pharmacological inhibition of DEAD-Box RNA Helicase 3 attenuates stress granule assembly. <i>Biochemical Pharmacology</i> , 2020 , 182, 114280	6	7
68	Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. <i>Lancet Oncology, The</i> , 2020 , 21, e575-e588	21.7	6
67	Clinical significance of a pvr1 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 245-259	4.9	14
66	Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. <i>ChemMedChem</i> , 2020 , 15, 1058-1066	3.7	4
65	Microglia morphology and proinflammatory signaling in the nucleus accumbens during nicotine withdrawal. <i>Science Advances</i> , 2019 , 5, eaax7031	14.3	30
64	Thiopurine-induced mitotic catastrophe in Rad51d-deficient mammalian cells. <i>Environmental and Molecular Mutagenesis</i> , 2018 , 59, 38-48	3.2	
63	The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin- α . <i>International Journal of Biochemistry and Cell Biology</i> , 2018 , 102, 151-160	5.6	21
62	Potential unintended consequences of getting rigorous with scientific rigor. <i>Carcinogenesis</i> , 2018 , 39, 26-27	4.6	
61	Nectin-4 is a breast cancer stem cell marker that induces WNT/ β -catenin signaling via Pi3k/Akt axis. <i>International Journal of Biochemistry and Cell Biology</i> , 2017 , 89, 85-94	5.6	39
60	Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. <i>Scientific Reports</i> , 2017 , 7, 43023	4.9	22
59	Human Papillomavirus Type 16 L2 DNA Methylation in Exfoliated Cervical Cells From College-Age Women. <i>Journal of Lower Genital Tract Disease</i> , 2016 , 20, 332-7	3.6	1
58	Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. <i>Biochemical Pharmacology</i> , 2016 , 105, 23-33	6	17

57	Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 433-42	8.3	8
56	Current assessment of polo-like kinases as anti-tumor drug targets. <i>Expert Opinion on Drug Discovery</i> , 2014 , 9, 773-89	6.2	32
55	The contribution of heavy metals in cigarette smoke condensate to malignant transformation of breast epithelial cells and in vivo initiation of neoplasia through induction of a PI3K-AKT-NFB cascade. <i>Toxicology and Applied Pharmacology</i> , 2014 , 274, 168-79	4.6	29
54	Regulatory and clinical considerations for biosimilar oncology drugs. <i>Lancet Oncology, The</i> , 2014 , 15, e594-e605	21.7	86
53	5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. <i>DNA Repair</i> , 2014 , 24, 15-25	4.3	28
52	Advances in understanding the coupling of DNA base modifying enzymes to processes involving base excision repair. <i>Advances in Cancer Research</i> , 2013 , 119, 63-106	5.9	10
51	SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013 , 743-744, 26-32	3.3	13
50	Silver-based nanoparticles induce apoptosis in human colon cancer cells mediated through p53. <i>Nanomedicine</i> , 2013 , 8, 1307-22	5.6	101
49	Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. <i>Carcinogenesis</i> , 2013 , 34, 277-86	4.6	56
48	Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. <i>Biochemical Pharmacology</i> , 2012 , 83, 741-6	6	21
47	Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. <i>International Journal of Cancer</i> , 2012 , 130, 1660-70	7.5	101
46	Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1683-92	6.1	17
45	Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism. <i>Oncology Research</i> , 2012 , 20, 81-91	4.8	77
44	The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair. <i>Molecular Cancer Research</i> , 2011 , 9, 206-14	6.6	6
43	PLK1 as an oncology target: current status and future potential. <i>Drug Discovery Today</i> , 2011 , 16, 619-25	8.8	86
42	Whole organism based techniques and approaches in early stage oncology drug discovery-patents and trends. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2011 , 5, 183-91		1
41	Cation exchange on the surface of gold nanorods with a polymerizable surfactant: polymerization, stability, and toxicity evaluation. <i>Langmuir</i> , 2010 , 26, 9328-33	4	83
40	RAD51D protects against MLH1-dependent cytotoxic responses to O(6)-methylguanine. <i>DNA Repair</i> , 2010 , 9, 458-67	4.3	14

39	DNA damage in barn swallows (<i>Hirundo rustica</i>) from the Chernobyl region detected by use of the comet assay. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2010 , 151, 271-7	3.2	36
38	Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. <i>Carcinogenesis</i> , 2009 , 30, 2123-9	4.6	32
37	Participation of DNA repair in the response to 5-fluorouracil. <i>Cellular and Molecular Life Sciences</i> , 2009 , 66, 788-99	10.3	160
36	Cellular uptake and cytotoxicity of gold nanorods: molecular origin of cytotoxicity and surface effects. <i>Small</i> , 2009 , 5, 701-8	11	842
35	Uracil in DNA: consequences for carcinogenesis and chemotherapy. <i>Biochemical Pharmacology</i> , 2008 , 76, 697-706	6	54
34	DNA damage and homologous recombination signaling induced by thymidylate deprivation. <i>Biochemical Pharmacology</i> , 2008 , 76, 987-96	6	15
33	Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. <i>DNA Repair</i> , 2008 , 7, 162-9	4.3	32
32	Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. <i>DNA Repair</i> , 2008 , 7, 1624-35	4.3	15
31	One-pot synthesis of silica-coated magnetic plasmonic tracer nanoparticles. <i>Chemical Communications</i> , 2008 , 6140-2	5.8	29
30	Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. <i>Chemical Research in Toxicology</i> , 2006 , 19, 1580-94	4	309
29	Developmental abnormalities in multiple proliferative tissues of Apc(Min/+) mice. <i>International Journal of Experimental Pathology</i> , 2006 , 87, 227-36	2.8	38
28	Effects of substrate specificity on initiating the base excision repair of N-methylpurines by variant human 3-methyladenine DNA glycosylases. <i>Chemical Research in Toxicology</i> , 2005 , 18, 87-94	4	14
27	Effect of protein binding on ultrafast DNA dynamics: characterization of a DNA:APE1 complex. <i>Biophysical Journal</i> , 2005 , 89, 4129-38	2.9	31
26	Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency. <i>Biochemical Pharmacology</i> , 2005 , 70, 1458-68	6	25
25	Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. <i>Small</i> , 2005 , 1, 325-711		1948
24	Oxanine DNA glycosylase activity from Mammalian alkyladenine glycosylase. <i>Journal of Biological Chemistry</i> , 2004 , 279, 38177-83	5.4	48
23	Involvement of base excision repair in response to therapy targeted at thymidylate synthase. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 747-53	6.1	15
22	Active-site clashes prevent the human 3-methyladenine DNA glycosylase from improperly removing bases. <i>Chemistry and Biology</i> , 2002 , 9, 1033-41		25

21	Influence of DNA structure on hypoxanthine and 1,N(6)-ethenoadenine removal by murine 3-methyladenine DNA glycosylase. <i>Carcinogenesis</i> , 2000 , 21, 901-8	4.6	25
20	Molecular basis for discriminating between normal and damaged bases by the human alkyladenine glycosylase, AAG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 13573-8	11.5	187
19	3-methyladenine DNA glycosylases: structure, function, and biological importance. <i>BioEssays</i> , 1999 , 21, 668-76	4.1	143
18	3-methyladenine DNA glycosylases: structure, function, and biological importance 1999 , 21, 668		3
17	Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. <i>Cancer Research</i> , 1998 , 58, 3965-73	10.1	35
16	Determination of the DNA sequence specificity of alkylation damage using cleavage-based assays. <i>Methods in Molecular Biology</i> , 1997 , 90, 147-56	1.4	5
15	The sequence specificity of alkylation for a series of benzoic acid mustard and imidazole-containing distamycin analogues: the importance of local sequence conformation. <i>Nucleic Acids Research</i> , 1997 , 25, 2359-64	20.1	4
14	Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 13087-92	11.5	191
13	Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. <i>British Journal of Cancer</i> , 1997 , 76, 1596-603	8.7	29
12	Alkylation specificity for a series of distamycin analogues that tether chlorambucil. <i>Anti-cancer Drug Design</i> , 1997 , 12, 49-60		2
11	Novel cytotoxic DNA sequence and minor groove targeted photosensitizers: conjugates of pyrene and netropsin analogues. <i>Bioorganic and Medicinal Chemistry</i> , 1995 , 3, 623-9	3.4	7
10	DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. <i>Nucleic Acids Research</i> , 1995 , 23, 81-7	20.1	85
9	Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. <i>Biochemistry</i> , 1995 , 34, 13034-41	3.2	37
8	Design, synthesis and biological evaluation of benzoic acid mustard derivatives of imidazole-containing and C-terminal carboxamide analogues of distamycin. <i>Drug Design and Discovery</i> , 1995 , 12, 323-35		2
7	Probing the importance of the second chloroethyl arm of a benzoic acid mustard derivative of an imidazole-containing analogue of distamycin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1994 , 4, 2421-2424	2.9	10
6	Synthesis and DNA binding properties of a series of N to C linked and imidazole containing analogues of distamycin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1994 , 4, 801-806	2.9	10
5	GC sequence specific recognition by an N-formamido, C-terminus-modified and imidazole-containing analogue of netropsin. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 4073-5	8.3	7
4	Structure-activity relationship of a series of nitrogen mustard- and pyrrole-containing minor groove-binding agents related to distamycin. <i>Anti-cancer Drug Design</i> , 1994 , 9, 511-25		5

3	In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. <i>Journal of Medicinal Chemistry</i> , 1993 , 36, 863-70	8.3	45
2	GC base sequence recognition by oligo(imidazolecarboxamide) and C-terminus-modified analogues of distamycin deduced from circular dichroism, proton nuclear magnetic resonance, and methidiumpropylethylenediaminetetraacetate-iron(II) footprinting studies. <i>Biochemistry</i> , 1993 , 32, 4237-45	3.2	363
1	Design, synthesis, and biological evaluation of DNA sequence and minor groove selective alkylating agents. <i>Anti-cancer Drug Design</i> , 1993 , 8, 173-92		11